MS, Pharmacy Administration
University of North Carolina, Chapel Hill, NC
Alicia Gilsenan, PhD, is a Senior Director and Head of Epidemiology within RTI-HS and a licensed pharmacist. Dr. Gilsenan’s primary area of expertise is pharmacoepidemiology and therapeutic risk management as well as the structured benefit-risk assessment of medications, biologics and devices. Since joining RTI in 1997, she has applied innovative approaches to the design, conduct, and analysis of both retrospective and prospective epidemiologic studies, most recently focusing on consultation, design, and implementation of postauthorization safety studies. She has directed multidisciplinary international teams for large primary and secondary data collection studies including multidatabase studies in the United States and Europe. Currently she leads several multinational safety surveillance studies, including a United States-based patient registry with more than 60,000 enrolled patients with annual linkage to more than 40 state cancer registries. Dr. Gilsenan has led and conducted systematic reviews of literature. Dr. Gilsenan has published within multiple therapeutic areas, including mental health, oncology, sexual functioning, cardiovascular health, respiratory health, and smoking cessation, as well as in the research areas of risk minimization measures and structured approaches to benefit-risk assessment.